Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 5/05/2025

1,424 CHF (-4,43%)

(-4,43%) 5/05/2025

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d -4,43%
1 week1w 0,00%
1 maand1m 34,85%
3 maanden3m 95,07%
6 maanden6m 61,82%
1 jaar1j -36,82%
5 jaar5j -95,41%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

2 mei 2025 · Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders · Persbericht

30 april 2025 · Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset · Persbericht

29 april 2025 · New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine · Persbericht

16 april 2025 · Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond · Persbericht

9 april 2025 · The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension · Persbericht

9 april 2025 · US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement · Persbericht

27 maart 2025 · Idorsia publishes its Annual Report 2024 · Persbericht

17 maart 2025 · US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients · Persbericht

14 maart 2025 · Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia · Persbericht

4 maart 2025 · Idorsia announces financial results for 2024 · Persbericht

Profiel Idorsia Ltd

CEO: Jean-Paul Clozel

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe